Biocon Pharma Gains US FDA Approval for Generic Liraglutide Injection

's wholly owned subsidiary, Biocon Pharma Ltd, received US FDA approval on March 12, 2026, for its Abbreviated New Drug Application (ANDA) covering Liraglutide Injection (gVictoza), 18 mg/3 mL (6 mg/mL) in single-patient-use prefilled pens. This generic version targets insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and above, serving as an adjunct to diet and exercise. The nod builds on Biocon Pharma's prior US FDA clearance for Liraglutide injection (gSaxenda) on February 24, 2026, strengthening its lineup of complex, vertically integrated injectables. Also Biocon Pharma reported FY24-25 turnover of ₹982.5 crore from its generic formulation operations. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.